| Dr Arun Manmadhan, MD | |
|
51 W 51st St Ste 330, New York, NY 10019-1951 | |
| (212) 326-8920 | |
| (212) 326-8925 |
| Full Name | Dr Arun Manmadhan |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 8 Years |
| Location | 51 W 51st St Ste 330, New York, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003262288 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 292035 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York-presbyterian Hospital | New york, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trustees Of Columbia University In The City Of New York | 8527972546 | 1895 |
News Archive
A University of California, San Diego research team led by bioengineer Gert Cauwenberghs is working to understand how the brain circuitry controls how we move. The goal is to develop new technologies to help patients with Parkinson's disease and other debilitating medical conditions navigate the world on their own.
Artimplant is following through on its strategy of focusing the company on the market even further and has now concluded negotiations under the Swedish Co-Determination Act, resulting in staff cutbacks within functions not related directly to sales. Once the periods of notice have been completed the annual saving at Artimplant AB will be approximately SEK 5 million.
Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.
From pacemakers constructed of materials that so closely mimic human tissues that a patient's body can't discern the difference to devices that bypass injured spinal cords to restore movement to paralyzed limbs, the possibilities presented by organic electronics read like something from a science fiction novel.
Saint Louis University researchers report in Molecular Metabolism new findings that the nuclear receptor REV-ERB appears to play a key role in muscle regeneration, suggesting the receptor may be a good target for new drugs to treat a variety of muscle disorders and injuries.
› Verified 7 days ago
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508266347 PECOS PAC ID: 8527972546 Enrollment ID: O20151201002613 |
News Archive
A University of California, San Diego research team led by bioengineer Gert Cauwenberghs is working to understand how the brain circuitry controls how we move. The goal is to develop new technologies to help patients with Parkinson's disease and other debilitating medical conditions navigate the world on their own.
Artimplant is following through on its strategy of focusing the company on the market even further and has now concluded negotiations under the Swedish Co-Determination Act, resulting in staff cutbacks within functions not related directly to sales. Once the periods of notice have been completed the annual saving at Artimplant AB will be approximately SEK 5 million.
Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.
From pacemakers constructed of materials that so closely mimic human tissues that a patient's body can't discern the difference to devices that bypass injured spinal cords to restore movement to paralyzed limbs, the possibilities presented by organic electronics read like something from a science fiction novel.
Saint Louis University researchers report in Molecular Metabolism new findings that the nuclear receptor REV-ERB appears to play a key role in muscle regeneration, suggesting the receptor may be a good target for new drugs to treat a variety of muscle disorders and injuries.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Arun Manmadhan, MD 51 W 51st St Ste 330, New York, NY 10019-1951 Ph: (212) 326-8920 | Dr Arun Manmadhan, MD 51 W 51st St Ste 330, New York, NY 10019-1951 Ph: (212) 326-8920 |
News Archive
A University of California, San Diego research team led by bioengineer Gert Cauwenberghs is working to understand how the brain circuitry controls how we move. The goal is to develop new technologies to help patients with Parkinson's disease and other debilitating medical conditions navigate the world on their own.
Artimplant is following through on its strategy of focusing the company on the market even further and has now concluded negotiations under the Swedish Co-Determination Act, resulting in staff cutbacks within functions not related directly to sales. Once the periods of notice have been completed the annual saving at Artimplant AB will be approximately SEK 5 million.
Axentis Pharma AG has initiated a clinical phase IIa trial to assess the safety and tolerability of a new therapeutic formulation for the treatment of severe pulmonary infection in cystic fibrosis patients. The new formulation allows an established therapeutic agent to be delivered directly to the site of infection. The forthcoming trial will also compare the effects of two different doses of the new drug.
From pacemakers constructed of materials that so closely mimic human tissues that a patient's body can't discern the difference to devices that bypass injured spinal cords to restore movement to paralyzed limbs, the possibilities presented by organic electronics read like something from a science fiction novel.
Saint Louis University researchers report in Molecular Metabolism new findings that the nuclear receptor REV-ERB appears to play a key role in muscle regeneration, suggesting the receptor may be a good target for new drugs to treat a variety of muscle disorders and injuries.
› Verified 7 days ago
Dr. Ravishankar Ramaswamy, MD, MS Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1440 Madison Avenue, New York, NY 10029 Phone: 212-659-8552 Fax: 212-860-9737 | |
Dr. Pietro Alessandro Ambrogio Canetta, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 622 W 168th St, Ph4-124, New York, NY 10032 Phone: 212-305-5020 Fax: 212-305-6692 | |
Dr. Rakhshan Mahmood Chida, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 327 E 17th St, New York, NY 10003 Phone: 212-420-5690 | |
Charles D Resor, Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 622 W 168th St, New York, NY 10032 Phone: 212-305-2913 | |
Dr. Jacqueline Yuey Lonier, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1150 Saint Nicholas Ave, New York, NY 10032 Phone: 212-851-5494 | |
Dr. Sharon Uralil, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 550 1st Ave, New York, NY 10016 Phone: 212-263-3293 | |
Diana Kantor, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 775 9th Ave, New York, NY 10019 Phone: 212-586-1550 |